Inappropriate left ventricular mass in patients with primary aldosteronism

Hypertension

Volumn 52, Issue 3, 2008, Pages 529-534

  Muiesan, Maria Lorenza ^a   Salvetti, Massimo ^a   Paini, Anna ^a   Agabiti Rosei, Claudia ^a   Monteduro, Cristina ^a   Galbassini, Gloria ^a   Belotti, Eugenia ^a   Aggiusti, Carlo ^a   Rizzoni, Damiano ^a   Castellano, Maurizio ^a   Agabiti Rosei, Enrico ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Aldosterone; Echocardiography; Hypertension arterial; Hypertrophy; Inappropriate LV mass

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN;

ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; ADAPTATION; BLOOD; ECHOGRAPHY; HYPERALDOSTERONISM; HYPERTENSION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PREVALENCE; STATISTICAL MODEL;

ADAPTATION, PHYSIOLOGICAL; ADULT; AGED; ALDOSTERONE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE;

EID: 52049103839     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.114140     Document Type: Article

References (53)

1. Frohlich ED. Risk mechanisms in hypertensive heart disease. Hypertension. 1999;34:782-789.
2. Agabiti Rosei E, Muiesan ML. Hypertensive Left ventricular hypertrophy: pathophysiological and clinical issues. Blood Press. 2001;10: 288-298.
3. Vakili B, Okin P, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-341.
4. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papa-demetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-2356.
5. de Simone G, Devereux RB, Kimball TR, Mureddu F, Roman MJ, Contaldo F, Daniels S. Interaction between body size and cardiac workload. Influence on left ventricular mass during body growth and adulthood. Hypertension. 1998;31:1077-1082.
6. Palmieri V, de Simone G, Roman MJ, Schwartz JE, Pickering TG, Devereux RB. Ambulatory blood pressure and metabolic abnormalities in hypertensive subjects with inappropriately high left ventricular mass [published correction appears in Hypertension. 2000;36:147]. Hypertension. 1999;34:1032-1040.
7. Palmieri V, Watchell K, Gerdts E, Bella J, Papademetriou V, Tuxen C, Nieminen MS, Dahlof B, de Simone G, Devereux RB. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE Study. Am Heart J. 2001;141:784-791.
8. de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J. 2008;29:741-747.
9. de Simone G, Palmieri V, Koren M, Mensah G, Roman MJ, Devereux RB. Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens. 2001;19:119 -125.
10. de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP, on behalf of the MAVI investigators. Prognosis of inappropriate LV mass in hypertension: the MAVI Study. Hypertension. 2002;40:470-476.
11. Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbassini G, Bonzi B, Poisa P, Belotti E, Agabiti Rosei C, Rizzoni D, Castellano M, Agabiti Rosei E. Inappropriate LV mass changes during treatment adversely affect cardiovascular prognosis in hypertensive patients. Hypertension. 2007;49:1077-1083.
12. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci. 2002;970:89-100.
13. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1-9.
14. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, Tiberio G, Giulini SM, Monteduro C, Garavelli G, Agabiti-Rosei E. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol. 1998;32:985-992.
15. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039-1045.
16. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension. 1997;29: 723-727.
17. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006;19: 13-18.
18. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocor-ticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911-918.
19. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
20. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
21. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension. 1984;6:717-723.
22. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens. 2006;24:737-745.
23. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, Giulini SM, Agabiti-Rosei E. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension. 1996;28:785-790.
24. Mantero F, Mattarello MJ, Albiger NM. Detecting and treating primary aldosteronism: primary aldosteronism. Exp Clin Endocrinol Diabetes. 2007;115:171-174.
25. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-mode standardization of the American Society of echocardiography: recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements. Circulation. 1978;58: 1072-1083.
26. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reicheck N. Echocardiographic assessment on left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
27. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056-1062.
28. Lang R, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard M, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer K, St John Sutton M, Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108.
29. Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E. Persistence of left ventricular hypertrophy is a stronger predictor of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years follow-up. J Hypertens. 1996;14(suppl 5):S43-S49.
30. Quinones MA, Otto C, Stoddard M, Waggoner A, Zoghbi W, Recommendations for quantifications of Doppler echocardiography: a report from the Doppler quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15:167-184.
31. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determination: echocardiographic-angiographic corre- lations in the presence or absence of asynergy. Am J Cardiol. 1976; 37:7-12.
32. Wallerson DC, Ganau A, Roman MJ, Devereux RB. Measurement of cardiac output by M-mode and two-dimensional echocardiography; application to patients with hypertension. Eur Heart J. 1990;11(suppl 1):67-78.
33. Working Group Report. How to diagnose diastolic heart failure -European Study on Diastolic Heart Failure. Eur Heart J. 1998;19: 990-1003.
34. Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheo-chromocytoma. Am J Hypertens. 1993;6:907-913.
35. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471-1478.
36. Shigematsu Y, Mareomi H, Hideki O, Hara Y, Hayashi Y, Kodama K, Katsuhiko K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension. 1997;29: 723-727.
37. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, Seki T, Demura R, Demura H. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res. 1997;20:85-90.
38. Penzo M, Palatini P, Rossi GP, Zanin L, Pessina AC. In primary aldo-steronism the circadian blood pressure rhythm is similar to that in primary hypertension. Clin Experim Hypertens. 1994;16:659-673.
39. Olsen M, Wachtell K, de Simone G, Palmieri V, Dige-Petersen H, Devereux RB, Ibsen H, Rokkedal J. Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? a LIFE substudy. J Hum Hypertens. 2004;18:437-443.
40. Fuller PJ, Young MJ. Mechanisms of mineralcorticoid action. Hypertension. 2005;46:1227-1235.
41. Okoshi M, Yan H, Okoshi K, Nakayama M, Adam JT, Schuldt A, O'Connel T, Simpson P, Lorell B. Aldosterone directly stimulates cardiac myocyte hypertrophy. J Cardiac Failure. 2004;10:511-518.
42. Lalevèe N, Rebsamen M, Barrère-Lemaire S, Perrier E, Nargeot J, Benitah JP, Rossier F. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;67:216-224.
43. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, Rezzani R, Boari GEM, Zani F, Miclini M, Tiberio GAM, Giulini SM, Agabiti-Rosei C, Bianchi R, Agabiti-Rosei E. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldoste-ronism. J Clin Endocrinol Metab. 2006;91:2638-2642.
44. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003;16:80-86.
45. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Moll Cell Cardiol. 2000;32:865-879.
46. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-27.
47. Strauch B, Petrak O, Wichterle D, Zelinka T, Holaj R, Widimsky J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens. 2006;19:909-914.
48. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006;48:89-96.
49. Campbell SE, Diaz-Arias AA, Weber KT. Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press. 1992;1:149-156.
50. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454-459.
51. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007;30:2349-2354.
52. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med. 1965;273:1135-1143.
53. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, Tiberio GAM, Giulini SM, Agabiti-Rosei E, Pessina A. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008;51:1366-1371.